EE9900465A - Uued ühendid - Google Patents

Uued ühendid

Info

Publication number
EE9900465A
EE9900465A EEP199900465A EEP9900465A EE9900465A EE 9900465 A EE9900465 A EE 9900465A EE P199900465 A EEP199900465 A EE P199900465A EE P9900465 A EEP9900465 A EE P9900465A EE 9900465 A EE9900465 A EE 9900465A
Authority
EE
Estonia
Prior art keywords
pct
date
new compounds
sec
pub
Prior art date
Application number
EEP199900465A
Other languages
English (en)
Estonian (et)
Inventor
Cheshire David
Cooper Martin
Donald David
Thorne Philip
Original Assignee
Astra Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharmaceuticals Limited filed Critical Astra Pharmaceuticals Limited
Publication of EE9900465A publication Critical patent/EE9900465A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
EEP199900465A 1997-04-15 1998-04-07 Uued ühendid EE9900465A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9701398A SE9701398D0 (sv) 1997-04-15 1997-04-15 Novel compounds
PCT/SE1998/000640 WO1998046606A1 (fr) 1997-04-15 1998-04-07 Nouveaux composes

Publications (1)

Publication Number Publication Date
EE9900465A true EE9900465A (et) 2000-04-17

Family

ID=20406576

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900465A EE9900465A (et) 1997-04-15 1998-04-07 Uued ühendid

Country Status (21)

Country Link
US (1) US6028074A (fr)
EP (1) EP0975636B1 (fr)
JP (1) JP2001520645A (fr)
KR (1) KR20010006350A (fr)
CN (1) CN1259951A (fr)
AT (1) ATE245648T1 (fr)
AU (1) AU733066B2 (fr)
BR (1) BR9808540A (fr)
CA (1) CA2286078A1 (fr)
DE (1) DE69816608T2 (fr)
EE (1) EE9900465A (fr)
HU (1) HUP0002104A3 (fr)
ID (1) ID22746A (fr)
IL (1) IL132153A0 (fr)
IS (1) IS5198A (fr)
NO (1) NO995006L (fr)
PL (1) PL336230A1 (fr)
SE (1) SE9701398D0 (fr)
SK (1) SK135699A3 (fr)
TR (1) TR199902538T2 (fr)
WO (1) WO1998046606A1 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US6875786B2 (en) 2001-03-01 2005-04-05 Smithkline Beecham Corporation Thrombopoietin mimetics
US20030211040A1 (en) 2001-08-31 2003-11-13 Paul Greengard Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
AR040083A1 (es) 2002-05-22 2005-03-16 Smithkline Beecham Corp Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
US9226885B2 (en) * 2005-05-24 2016-01-05 Allium Vitalis Incorporated Personal care and medicinal products incorporating bound organosulfur groups
CN103467471A (zh) 2005-06-06 2013-12-25 武田药品工业株式会社 有机化合物
JP5453086B2 (ja) * 2006-06-06 2014-03-26 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2008063505A1 (fr) 2006-11-13 2008-05-29 Intra-Cellular Therapies, Inc. Composés organiques
WO2008070095A1 (fr) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Nouvelles utilisations
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
US8846693B2 (en) 2007-12-06 2014-09-30 Intra-Cellular Therapies, Inc. Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones
KR101227738B1 (ko) 2007-12-06 2013-01-29 다케다 야쿠힌 고교 가부시키가이샤 유기 화합물
EP2367429B1 (fr) 2008-12-06 2017-06-07 Intra-Cellular Therapies, Inc. Composés organiques
GEP20146046B (en) * 2008-12-06 2014-02-25 Intracellular Therapies Inc Organic compounds
EP2367428B1 (fr) 2008-12-06 2016-04-06 Intra-Cellular Therapies, Inc. Composés organiques
MX2011005936A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
MX2011005937A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
MA32940B1 (fr) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
WO2010098839A1 (fr) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Inhibiteur de pde 1 pour troubles ophtalmiques
PT2411395E (pt) 2009-03-23 2013-06-06 Glenmark Pharmaceuticals Sa Derivados de furopirimidinadiona como moduladores de trpa1
DK2411397T3 (da) 2009-03-23 2013-08-05 Glenmark Pharmaceuticals Sa Isothiazol-pyrimidindionderivater som modulatorer af TRPA1
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
ES2456515T3 (es) * 2009-03-23 2014-04-22 Glenmark Pharmaceuticals S.A. Derivados de pirimidindiona fusionados como moduladores de TRPA1
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP2012528184A (ja) 2009-05-29 2012-11-12 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー トロンボポエチンアゴニスト化合物の投与の方法
EP2461673A4 (fr) 2009-08-05 2013-08-07 Intra Cellular Therapies Inc Nouvelles protéines régulatrices et nouveaux inhibiteurs
JP5879336B2 (ja) 2010-05-31 2016-03-08 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
EP2590657A4 (fr) 2010-05-31 2014-02-12 Intra Cellular Therapies Inc Composés organiques
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153138A1 (fr) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Composés organiques
WO2012171016A1 (fr) 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Composés organiques
CA2873570C (fr) 2012-06-08 2016-11-01 Glenmark Pharmaceuticals S.A. Amides de composes de 2-amino-4-arylthiazole et leurs sels comme modulateurs trpa1
WO2014127331A1 (fr) 2013-02-17 2014-08-21 Intra-Cellular Therapies, Inc. Nouvelles utilisations
MX2015013042A (es) 2013-03-15 2016-05-05 Intra Cellular Therapies Inc Compuestos organicos.
EP3479825B1 (fr) 2013-03-15 2021-02-17 Intra-Cellular Therapies, Inc. Inhibiteurs de pde1 utilisés dans le traitement et/ou la prévention de maladies ou de troubles du snc ou du snp
US9849132B2 (en) 2014-01-08 2017-12-26 Intra-Cellular Therapies, Inc. Products and pharmaceutical compositions
ES2732442T3 (es) 2014-06-20 2019-11-22 Intra Cellular Therapies Inc Compuestos orgánicos
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
JP6591530B2 (ja) 2014-08-07 2019-10-16 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US10150774B2 (en) 2014-09-17 2018-12-11 Intra-Cellular Therapies, Inc. Compounds and methods
US10105349B2 (en) 2014-12-06 2018-10-23 Intra-Cellular Therapies, Inc. Organic compounds
KR102557603B1 (ko) 2014-12-06 2023-07-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2017172795A1 (fr) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Nouvelles compositions et méthodes
WO2018015088A1 (fr) * 2016-06-23 2018-01-25 F. Hoffmann-La Roche Ag Nouveaux dérivés de triazolo[4,5-d]pyrimidine
EP3509589B1 (fr) 2016-09-12 2021-11-17 Intra-Cellular Therapies, Inc. Nouvelles utilisations
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982003626A1 (fr) * 1981-04-22 1982-10-28 Gauri Kailash Kumar Nouveaux derives de la pyrazolo (3, 4-d) pyrimidine, procede de leur preparation et remede les contenant
US4603203A (en) * 1983-12-14 1986-07-29 Takeda Chemical Industries, Ltd. 3-aminopyrazolo[3,4-d]pyrimidine derivatives and production thereof
EP0237289A3 (fr) * 1986-03-14 1988-07-27 Takeda Chemical Industries, Ltd. Dérivés de pyrazolo[3,4-d]pyrimidine, leur préparation et utilisation
WO1994013643A1 (fr) * 1992-12-17 1994-06-23 Pfizer Inc. Pyrazoles et pyrazolopyrimidines presentant une activite d'antagonistes du facteur de liberation de la cortitrophine
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines

Also Published As

Publication number Publication date
SE9701398D0 (sv) 1997-04-15
ATE245648T1 (de) 2003-08-15
DE69816608D1 (de) 2003-08-28
EP0975636A1 (fr) 2000-02-02
JP2001520645A (ja) 2001-10-30
CN1259951A (zh) 2000-07-12
NO995006D0 (no) 1999-10-14
US6028074A (en) 2000-02-22
DE69816608T2 (de) 2004-04-15
HUP0002104A3 (en) 2002-03-28
ID22746A (id) 1999-12-09
IL132153A0 (en) 2001-03-19
BR9808540A (pt) 2000-05-23
KR20010006350A (ko) 2001-01-26
IS5198A (is) 1999-09-27
AU733066B2 (en) 2001-05-03
EP0975636B1 (fr) 2003-07-23
AU7090998A (en) 1998-11-11
SK135699A3 (en) 2000-05-16
HUP0002104A2 (hu) 2001-01-29
TR199902538T2 (xx) 2000-02-21
NO995006L (no) 1999-10-14
CA2286078A1 (fr) 1998-10-22
PL336230A1 (en) 2000-06-19
WO1998046606A1 (fr) 1998-10-22

Similar Documents

Publication Publication Date Title
EE9900465A (et) Uued ühendid
EE200000318A (et) Uudsed ühendid
PT991653E (pt) Novos compostos
EE9900315A (et) Pürrolo[3,4-d]pürimidinooni derivaadid ja nende kasutamine ravimitena
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
SE9702772D0 (sv) Novel compounds
HUT75776A (en) Pyrazolo and pyrrolopyridines, their using, pharmaceutical compositions containing them and intermediates
HUP0104318A2 (hu) cGMP PDE-5 inhibitort tartalmazó szabályzottan hatóanyagot felszabadító gyógyászati készítmények
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
HK1075450A1 (en) heterocyclic compunds, process for their preparation and pharmaceutical compositions containing thenm and thier use in medicine
HUP0002346A1 (hu) Emlősök elmezavarainak kezelésére szolgáló gyógyszerkészítmény
DE69911785D1 (de) Triazolo[4,5-d]pyrimidin-verbindungen
HUP0100611A2 (hu) Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére
AU3862997A (en) Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof
AU7436098A (en) Use of mizolastine for preparing a medicine for treating inflammation